Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

LEO PHARMA A/S - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

0.001 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   2.2% 2.1% 3.3% 4.7% 3.2% 2.8% 2.2% 2.2%   Credit score (0-100)   67 68 53 45 55 60 66 66   Credit rating   BBB A BBB BBB BBB BBB BBB BBB   Credit limit (bDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 0.001 Income statement (bDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   11 10 10 11 11 12 12 12   Gross profit   7.5 6.8 6.0 6.3 7.2 7.5 0.0 0.0   EBITDA   -1.3 -0.7 -4.2 -3.3 -1.7 -1.1 0.0 0.0   EBIT   -1.3 -0.7 -4.2 -3.3 -1.7 -1.1 0.0 0.0   Pre-tax profit (PTP)   -1.7 -1.1 -4.8 -4.1 -2.8 -2.0 0.0 0.0   Net earnings   -1.3 -1.0 -4.9 -4.1 -3.6 -1.8 0.0 0.0   Pre-tax profit without non-rec. items   -1.7 -1.1 -4.8 -4.1 -2.8 -2.0 0.0 0.0     See the entire income statement 0.001 Balance sheet (bDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   3.3 4.1 4.5 4.7 4.5 4.4 0.0 0.0   Shareholders equity total   8.1 6.9 5.5 1.9 4.5 2.7 2.6 2.6   Interest-bearing liabilities   9.7 10.2 10.6 14.2 10.7 11.0 2.4 2.4   Balance sheet total (assets)   24.8 23.9 23.7 22.9 21.0 20.2 4.9 4.9   Net Debt   9.3 9.4 10.1 14.0 10.5 10.8 2.4 2.4     See the entire balance sheet 0.001 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   11 10 10 11 11 12 12 12   Net sales growth   3.8% -6.2% -1.7% 6.9% 7.1% 9.3% 0.0% 0.0%   Gross profit   7.5 6.8 6.0 6.3 7.2 7.5 0.0 0.0   Gross profit growth   1.2% -9.1% -11.5% 4.8% 14.6% 4.4% -100.0% 0.0%   Employees   0 0 5,804 5,252 4,490 4,184 0 0   Employee growth %   0.0% 0.0% 0.0% -9.5% -14.5% -6.8% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   25 24 24 23 21 20 5 5   Balance sheet change%   52.1% -3.7% -0.7% -3.2% -8.6% -3.8% -75.5% 0.0%   Added value   -1.3 -0.7 -4.2 -3.3 -1.7 -1.1 0.0 0.0   Added value %   -12.2% -7.2% -41.7% -31.1% -14.9% -9.2% 0.0% 0.0%   Investments   5 -0 -0 -1 -2 -1 -4 0   Net sales trend   1.0 -1.0 -2.0 1.0 2.0 3.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 -5.0 0.0 0.0   0.001 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   -12.2% -7.2% -41.7% -31.1% -14.9% -9.2% 0.0% 0.0%   EBIT %   -12.2% -7.2% -41.7% -31.1% -14.9% -9.2% 0.0% 0.0%   EBIT to gross profit (%)   -17.6% -10.7% -69.3% -52.7% -23.6% -15.2% 0.0% 0.0%   Net Earnings %   -11.9% -9.4% -48.9% -38.6% -31.7% -14.3% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -11.9% -9.4% -48.9% -38.6% -31.7% -14.3% 0.0% 0.0%   Pre tax profit less extraordinaries %   -15.8% -10.7% -47.8% -38.5% -24.5% -15.7% 0.0% 0.0%   ROA %   -6.5% -2.9% -17.4% -14.2% -7.5% -4.9% 0.0% 0.0%   ROI %   -8.2% -3.6% -22.5% -18.6% -9.5% -6.2% 0.0% 0.0%   ROE %   -14.6% -12.7% -78.0% -109.8% -111.5% -49.1% 0.0% 0.0%   0.001 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   32.7% 29.1% 23.4% 8.5% 21.6% 13.4% 52.4% 52.4%   Relative indebtedness %   154.3% 166.8% 182.4% 197.2% 144.2% 140.1% 18.9% 18.9%   Relative net indebtedness %   149.9% 159.6% 178.0% 194.7% 142.3% 138.3% 18.9% 18.9%   Net int. bear. debt to EBITDA, %   -705.7% -1,299.9% -243.5% -422.0% -619.8% -941.7% 0.0% 0.0%   Gearing %   120.5% 146.3% 190.6% 731.9% 237.5% 406.5% 90.7% 90.7%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   6.6% 3.8% 6.0% 6.3% 9.1% 8.7% 0.0% 0.0%   0.001 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   1.1 0.9 0.6 0.6 0.8 0.6 0.0 0.0   Current Ratio   1.6 1.4 1.2 1.4 1.8 1.5 0.0 0.0   Cash and cash equivalent   0.5 0.7 0.4 0.3 0.2 0.2 0.0 0.0   0.001 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   112.3 87.9 82.6 73.3 68.6 69.4 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   87.2% 85.0% 86.2% 76.8% 76.2% 69.7% 0.0% 0.0%   Net working capital   2.9 2.4 1.2 2.3 3.7 2.8 -1.2 -1.2   Net working capital %   26.6% 23.5% 11.9% 21.9% 32.7% 22.1% -9.4% -9.4%   0.001 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 -0 -0 -0 -0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 -0 -0 -0 -0 0 0   EBIT / employee   0 0 -0 -0 -0 -0 0 0   Net earnings / employee   0 0 -0 -0 -0 -0 0 0